LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Dipeptidase 2 (DPEP2) is a protein which in humans is encoded by the DPEP2 gene. DPEP2 belongs to the membrane-bound dipeptidase (EC 3.4.13.19) family. These enzymes hydrolyze a variety of dipeptides, including leukotriene D4, the beta-lactam ring of some antibiotics, and cystinyl-bis-glycine (cys-bis-gly) formed during glutathione degradation.
In 2019, the FDA and EMA approved givosiran for the treatment of adults with acute hepatic porphyria (AHP). The FDA also granted givosiran a breakthrough therapy designation, priority review designation, and orphan drug designation for the treatment of acute hepatic porphyria (AHP) in November 2019. By 2020, givosiran received EMA approval. Givosiran is an siRNA that breaks down aminolevulinic acid synthase 1 (ALAS1) mRNA in the liver. Breaking down ALAS1 mRNA prevents toxins (responsible for neurovisceral attacks and AHP disease) such as aminolevulinic acid (ALA) and porphobilinogen (PBG) from accumulating. To facilitate entry into the cytoplasm, givosiran uses GalNAc ligands and enters into liver cells. The medication is administered subcutaneously by a healthcare professional with dosing based on body weight. Warnings and precautions include risk of anaphylactic reactions, hepatic toxicity, renal toxicity and injection site reactions. Lumasiran was approved as a siRNA-based medication in 2020 for use in both the European Union and the United States. This medication is used for the treatment of primary hyperoxaluria type 1 (PH1) in pediatric and adult populations. The drug is designed to reduce hepatic oxalate production and urinary oxalate levels through RNAi by targeting hydroxyacid oxidase 1 (HAO1) mRNA for breakdown. Lowering HAO1 enzyme levels reduces the oxidation of glycolate to glyoxylate (which is a substrate for oxalate). Lumasiran is administered subcutaneously by a healthcare professional with dosing based on body weight.
Cardiolipin (IUPAC name 1,3-bis(sn-3’-phosphatidyl)-sn-glycerol, "sn" designating stereospecific numbering) is an important component of the inner mitochondrial membrane, where it constitutes about 20% of the total lipid composition. It can also be found in the membranes of most bacteria. The name "cardiolipin" is derived from the fact that it was first found in animal hearts. It was first isolated from the beef heart in the early 1940s by Mary C. Pangborn. In mammalian cells, but also in plant cells, cardiolipin (CL) is found almost exclusively in the inner mitochondrial membrane, where it is essential for the optimal function of numerous enzymes that are involved in mitochondrial energy metabolism.
=== Ajinomoto === In 2004, the market for aspartame, in which Ajinomoto, the world's largest aspartame manufacturer, had a 40% share, was 14,000 metric tons (15,000 short tons; 14,000 long tons) a year, and consumption of the product was rising by 2% a year. Ajinomoto acquired its aspartame business in 2000 from Monsanto for $67 million (equivalent to $116 million in 2024). In 2007, Asda was the first British supermarket chain to remove all artificial flavorings and colors in its store brand foods. In 2008, Ajinomoto sued Asda, part of Walmart, for a malicious falsehood action concerning its aspartame product when the substance was listed as excluded from the chain's product line, along with other "nasties". In July 2009, a British court ruled in favor of Asda. In June 2010, an appeals court reversed the decision, allowing Ajinomoto to pursue a case against Asda to protect aspartame's reputation. Asda said that it would continue to use the term "no nasties" on its own-label products, but the suit was settled in 2011 with Asda choosing to remove references to aspartame from its packaging. In November 2009, Ajinomoto announced a new brand name for its aspartame sweetener – AminoSweet.
Sources: en.wikipedia.org
== In the aquarium == The minimum tank size requirement for the Ember tetras is at least 10 gallons with few live aquarium plants. Ember tetras should be kept in acidic water with a pH near 6.6, and although their native habitat has very soft water, they have adapted quite well to a wide range of hardness (5–17 dGH). The recommended temperature range is 23–29 °C (73–84 °F). Ideally their tank should contain live plants , a darker substrate, and open water for swimming. Ember tetras should be kept in groups of at least 6, though the recommended number is 9–10, in order to promote schooling. They appreciate a heavily planted aquarium ideally with a small area shaded from direct light, and will spend a lot of time swimming through planted areas, which also offer some protection for their fry. Ember tetras will school with other tetras, such as the neon tetra, but may become stressed by the presence of significantly larger fish. These fish swim at the middle level of the aquarium, and they do not feed from the bottom of the tank. Therefore, it is recommended that they are kept with other bottom dwelling fish (such as pygmy corydoras) so that leftover food is then eaten up off the substrate and not left to waste. Ember tetras can be fed a variety of foods, including flake, frozen, and freeze dried food. Small live foods like worms and brine shrimp are also recommended, as they bring out the fish's colors. In a well maintained heavily planted aquarium, ember tetras have been known to live ten years or more.
== Ecology == In its native habitat Vanilla planifolia depends on one or more pollinators. Several species of bee have been proposed including Euglossa species, Eulaema cingulata, Eulaema polychroma, Eulaema meriana, and Melipona beecheii for pollination. However, no definitive observation of pollination is recorded and the size of M. beecheii in particular make it unlikely to be a pollinator of this species of orchid, though unpublished observations suggest that Euglossa (reported as E. viridissima, but this species has historically been confused with other Euglossa species) might be capable of completing pollination. Attempts to document the visitation of V. planifolia in the Yucatán peninsula of Mexico failed to record any visitation by any stingless bees or orchid bees (including Melipona, Eulaema, and Euglossa), leaving the identity of its natural pollinators as yet unresolved. Though the seeds of Vanilla planifolia are very small, they are relatively large for an orchid and are not dispersed by the wind. Instead they spread through the rainforest habitat by many different animals. Male orchid bees in the tribe Euglossini in the genera Euglossa and Eulaema exhibit fragrance-collecting behavior with the fruits. Specific species observed removing seeds as part of this behavior include Euglossa bursigera, Euglossa ignita, Euglossa tridentata, and Eulaema cingulata. Conversely female stingless bees remove the pulp of the fruit in a behavior consistent with nest-building activities. The two species observed distributing V.
Once on the membrane, the various adaptors would work together to package different types of cargo into the newly forming vesicle. Robinson and her researchers use several approaches to look for novel adaptors and other components of the trafficking machinery, including proteomic analyses of sub cellular fractions, genome-wide siRNA library screening, insertional mutagenesis, and a new method they developed for rapidly inactivating proteins, called 'knock sideways'. Her current projects include establishing the functions of AP-1 and other adaptors in differentiated cells; matching up machinery and cargo proteins; investigating how clathrin and adaptors are hijacked by the HIV-1-encoded protein Nef; determine why mutations in the non-clathrin adaptors AP-4 and AP-5 cause hereditary spastic paraplegia; and exploring the evolution of adaptors. Her laboratory uses many techniques including immunolocalisation at the light and electron microscope levels, sub cellular fractionation, protein purification, proteomics, flow cytometry, live cell imaging, and X-ray crystallography.
=== Criminal justice and law enforcement === On April 1, 2019, Pritzker created Illinois's Youth Parole system. Pritzker signed into law Senate Bill 1890, whose goal is to crack down on human trafficking. It requires hospitality business owners to train their employees to recognize victims of trafficking and to teach them the protocols of reporting to authorities. It also establishes penalties for human trafficking, including a fine of up to $100,000 and a Class 1 Felony charge. While serving in the Illinois Senate, Barack Obama sponsored an initiative that would collect data on traffic stops. This was codified when Pritzker signed House Bill 1613 into law. It creates a task force to collect and analyze data on traffic stops to address racial disparities. The task force was to report to the governor and the General Assembly by March 1, 2022, and every three years thereafter. According to the governor's office, the 2019–20 budget funded two classes of Illinois State Police cadets. In July 2019, Pritzker signed a bill that increases penalties for drivers who got involved in a road incident with injuries while texting. Under this bill, a person who causes serious injuries due to driving while texting could be fined at least $1,000 and have their driver's license suspended for a year. The law took effect immediately. In the same month, he signed House Bill 2045, ending the practice of collecting a $5 copay for offsite medical and dental treatments from people detained at a juvenile correction facility. This took effect in January 2020.
Otherwise, the carbonyl branch is homologous between the two domains and consists of the reduction of another molecule of CO2 to a carbonyl residue bound to an enzyme, catalyzed by the CO dehydrogenase/acetyl-CoA synthase. This key enzyme is also the catalyst for the formation of acetyl-CoA starting from the products of the previous reactions, the methyl and the carbonyl residues. This carbon fixation pathway requires only one molecule of ATP for the production of one molecule of pyruvate, which makes this process one of the main choice for chemolithoautotrophs limited in energy and living in anaerobic conditions.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.